Companies / NUZ

NEURIZON THERAPEUTICS LIMITED

ASX:NUZPharmaceuticals, Biotechnology & Life Sciences
775.1M shares on issueASX (delayed) · as of 28 July 2026$0.060price · delayed$46.5Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 58% in 24 months; 2 cash raises in 24 months

Cash runway1.3 quarters of funding
Share-count growth (24m)57.8%
Raise cadence (24m)2 cash raises
Options & rights overhang4.9% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

NEURIZON THERAPEUTICS LIMITED's ordinary share count grew 57.8% between November 2024 and July 2026, to 775M shares. The company raised capital twice in that period for total proceeds of A$20.8M, most recently a Placement & Entitlement Offer in December 2025 raising A$15.6M. Options and rights on issue could convert into 38M new shares, equal to 4.9% of the current share count, with 0% in the money and the nearest expiry in February 2028. At the March 2026 quarter the company reported A$8.2M in available cash, equivalent to 1.3 quarters of funding at its recent spending rate. One proposed securities issue (Appendix 3B) is pending with an expected issue date in September 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
4.9%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
1.3 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 775.1M per ASX (delayed) (28 July 2026).
551.4M633.5M715.6MDec 24Sept 25July 26Cash raise · 18 Dec 2025Cash raise · 15 Sept 2025

Cash runway

1.3 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$8.2M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
16 July 20262A · quoted issueNUZ : ORDINARY FULLY PAID775.1MAppendix 2A
14 July 20263H · cancellationNUZ : ORDINARY FULLY PAID763.6MAppendix 3H
29 June 20263H · cancellationNUZ : ORDINARY FULLY PAID763.6MAppendix 3H
19 June 20262A · quoted issueNUZ : ORDINARY FULLY PAID763.6MAppendix 2A
2 June 20262A · quoted issueNUZ : ORDINARY FULLY PAID754.0MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

$15.6M
Placement & Entitlement Offer
18 Dec 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

4.9%
Total overhang · of current shares
0.0%
In the money · at current price
37.8M
Potential new shares
Feb 2028
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
30 June 2026Marcus HughesBuy——$3k3Y notice
29 June 2026Marcus HughesBuy——$1943Y notice
26 June 2026Marcus HughesBuy——$2k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

16 July 2026$PHEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
16 July 2026Application for quotation of securities - NUZ
14 July 2026Notification of cessation of securities - NUZ
1 July 2026Neurizon Invites Investors to Melbourne Briefing
30 June 2026Change of Director's Interest Notice
29 June 2026Proposed issue of securities - NUZ
29 June 2026Notification of cessation of securities - NUZ
23 June 2026New NUZ-001 Mechanistic Data Presented at BIO 2026
19 June 2026Application for quotation of securities - NUZ
16 June 2026$PNeurizon executes long-term supply agreement with Elanco
11 June 2026$PHEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
2 June 2026Application for quotation of securities - NUZ
28 May 2026Webinar presentation - Regimen I expands to 240 participants
26 May 2026$PHEALEY ALS Trial Regimen I Expands to 240 Participants
12 May 2026$PEthics Approval Received for NUZ-001 Oral Liquid P1 Study
12 May 2026Final Director's Interest Notice
12 May 2026Initial Director's Interest Notice
11 May 2026Australian Microcap Investment Conference Presentation
7 May 2026Neurizon Strengthens Board for the Next Growth Phase
4 May 2026Change of Director's Interest Notices

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.